ACE and cancer: So far, the therapeutic options currently available for the handling of cardiac abnormalities in cancer patients are limited, such as Angiotensin-converting enzyme (ACE) inhibitors, beta-blockers (BB), and the hydralazine-nitrate combination, which mitigate the symptoms and signs, with little or no demonstrated impact on cardiomyocyte death [19].